Feeds › Clinical trial updates
Clinical trial updates
Drug and device trials that companies register on ClinicalTrials.gov: newly completed phase 3 studies, changes of status and the dates a study is due to finish.
About this data
- What it is
- ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
- Who files it
- The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
- How current
- We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
- Terms
- ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
- Worth knowing
- A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
- Not to be confused with
- FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.
All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.
Source and freshness · Information, not investment advice (disclaimer).
Studies updated per day, last 30 days
All industry-sponsored studies Sponsor matched to a public company
By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.
Latest clinical trial updates
Showing: ticker IRD · All recent updates
Studies by the date their record was last updated.
| Updated | Study | SponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private. | PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages. | StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time). | Enrolled | Primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update. | Source |
|---|---|---|---|---|---|---|---|
| Oct 30, 2026 | Safety and Tolerability of Subretinal OPGx-RDH12-1001 for LCA-Associated Inherited Retinal Degenera… NCT07681778 · Leber Congenital Amaurosis, Leber Congenital Amaurosis (LCA) OPGx-RDH12 | IRD Opus Genetics, Inc | Phase 1/2 | Recruiting was not yet recruiting | 10 | Dec 2032 | Registry ↗ |
| Oct 30, 2026 | Safety and Efficacy of Nyxol Eye Drops as a Single Agent and With Adjunctive Low-Dose Pilocarpine E… NCT05646719 · Presbyopia Phentolamine Opthalmic Solution 0.75%, Placebo | IRD Opus Genetics, Inc | Phase 3 | Completed | 333 | Oct 11, 2023 | Registry ↗ |
| Oct 30, 2026 | Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis in Pe… NCT05223478 · Mydriasis, Dilation Phentolamine Ophthalmic Solution 0.75%, Phentolamine Ophtha… | IRD Opus Genetics, Inc | Phase 3 | Completed | 23 | Apr 18, 2022 | Registry ↗ |
| Oct 30, 2026 | Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-… NCT05134974 · Mydriasis, Dilation Phentolamine Ophthalmic Solution 0.75%, Phentolamine Ophtha… | IRD Opus Genetics, Inc | Phase 3 | Completed | 368 | Mar 18, 2022 | Registry ↗ |
| Oct 30, 2026 | Study of the Safety and Efficacy of APX3330 in Diabetic Retinopathy NCT04692688 · Diabetic Retinopathy, Diabetic Macular Edema APX3330, Placebo | IRD Opus Genetics, Inc | Phase 2 | Completed | 103 | Jan 25, 2023 | Registry ↗ |
| Oct 30, 2026 | Safety and Efficacy of Nyxol With Pilocarpine Eye Drops in Subjects With Presbyopia NCT04675151 · Presbyopia Phentolamine Ophthalmic Solution 0.75%, Pilocarpine | IRD Opus Genetics, Inc | Phase 2 | Completed | 150 | May 17, 2021 | Registry ↗ |
| Oct 30, 2026 | Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) in Subjects With Dim Light Vi… NCT04638660 · Dim Light Vision Disturbances Phentolamine Ophthalmic Solution 0.75%, Phentolamine Ophtha… | IRD Opus Genetics, Inc | Phase 3 | Completed | 144 | May 19, 2022 | Registry ↗ |
| Oct 30, 2026 | Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-… NCT04620213 · Mydriasis, Dilation Phentolamine Ophthalmic Solution 0.75%, Phentolamine Ophtha… | IRD Opus Genetics, Inc | Phase 3 | Completed | 185 | Dec 23, 2020 | Registry ↗ |
| Oct 30, 2026 | Safety and Efficacy of Ophthalmic Phentolamine Mesylate to Reverse Pharmacologically Induced Mydria… NCT04024891 · Mydriasis, Dilation Phentolamine Mesylate Ophthalmic Solution 1%, Phentolamine… | IRD Opus Genetics, Inc | Phase 2 | Completed | 32 | Sep 17, 2019 | Registry ↗ |
| Oct 30, 2026 | Single Dose Study of Phentolamine Mesylate Eye Drops in Patients With Severe Night Vision Disturban… NCT04004507 · Decrease in Night Vision, Disturbance; Vision, Loss Phentolamine Mesylate Ophthalmic Solution 1%, Phentolamine… | IRD Opus Genetics, Inc | Phase 2 | Completed | 24 | Oct 2007 | Registry ↗ |
| Oct 30, 2026 | Safety and Efficacy of Ophthalmic Phentolamine Mesylate in Glaucoma NCT03960866 · Open Angle Glaucoma, Ocular Hypertension Phentolamine Mesylate Ophthalmic Solution 1%, Phentolamine… | IRD Opus Genetics, Inc | Phase 2 | Completed | 39 | Sep 11, 2019 | Registry ↗ |
| Oct 30, 2026 | The Safety and Efficacy of Phentolamine Mesylate Ophthalmic Solution in Subjects With Severe Night… NCT01703559 · Night Vision Complaints, Decrease in Night Vision Phentolamine Mesylate Ophthalmic Solution 1.0%, Phentolamin… | IRD Opus Genetics, Inc | Phase 2 | Completed | 60 | Apr 16, 2012 | Registry ↗ |
| Oct 26, 2026 | Evaluate Efficacy and Safety of POS to Improve Distance-corrected Near Visual in Participants With… NCT06542497 · Presbyopia 0.75% phentolamine ophthalmic solution, Placebo | IRD Opus Genetics, Inc | Phase 3 | Completed | 569 | Apr 3, 2025 | Registry ↗ |
| Oct 26, 2026 | Safety and Efficacy of 0.75% Phentolamine Ophthalmic Solution in Subjects With Post-refractive Surg… NCT06349759 · Mesopic Vision, Night Vision Loss phentolamine ophthalmic solution 0.75%, a non-selective alp… | IRD Opus Genetics, Inc | Phase 3 | Completed | 200 | Apr 17, 2025 | Registry ↗ |
| Oct 14, 2026 | OPI-NXYDLD-303 Safety and Efficacy of Phentolamine Ophthalmic Solution in Keratorefractive Surgery… NCT07140783 · Vision Loss Night, Vision Disorders 0.75% Phentolamine Ophthalmic Solution, Placebo | IRD Opus Genetics, Inc | Phase 3 | Recruiting | 580 | Aug 2027 | Registry ↗ |
| Sep 24, 2026 | Safety and Tolerability of Subretinally Injected OPGx-BEST1 in Patients With Best Vitelliform Macul… NCT07185256 · ARB, BVMD OPGx-BEST1 | IRD Opus Genetics, Inc | Phase 1/2 | Recruiting | 10 | Aug 2030 | Registry ↗ |
| Feb 19, 2026 | Safety and Tolerability Subretinal OPGx-001 for LCA5-Associated Inherited Retinal Degeneration (LCA… NCT05616793 · LCA5 AAV8.hLCA5 | IRD Opus Genetics, Inc | Phase 1/2 | Recruiting | 22 | Jun 15, 2028 | Registry ↗ |
17 items, most recent first (up to 50). Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 6:20 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances